Amryt’s first full year as a public company, Cathal Friel leaves board
February 9, 2017Amryt’s non-executive director Cathal Friel will step down from the board the last day of March 2017, the orphan diseases focused pharmaceutical company said Thursday.
According to the Amryt’s press release, Friel contributed especially with the admission of the company’s shares to AIM and ESM in spring 2016, by the reverse takeover of Fastnet Equity where he served as Executive Chairman.
The reason for his leaving after one year in March, is “focusing on his other business interests”.
Friel said: “Having helped Amryt with its admission to AIM and over its first full year as a public company, I leave the Board with great confidence in the executive team and remain very excited about the Group’s future potential.”
